Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$11.49 USD
-0.15 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.53 +0.04 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NTLA 11.49 -0.15(-1.29%)
Will NTLA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Other News for NTLA
NTLA Awards Inducement Grant Amid Employment Expansion
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA ...
Intellia Therapeutics announces employee inducement grants
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options